Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752427 | 0.91 | TDP1 (0.49) | TDP1NPSR1GAAMEN1KMT2A | |
| SCHEMBL754764 | 0.84 | TDP1 (0.39) | TDP1NPSR1GAAMEN1KMT2A | |
| SCHEMBL1143295 | 0.81 | TDP1 (0.49) | TDP1NPSR1GAAMEN1KMT2A | |
| SCHEMBL3056923 | 0.78 | TDP1 (0.54) | TDP1NPSR1GAAMEN1KMT2A | |
| SCHEMBL4743276 | 0.78 | TDP1 (0.46) | TDP1NPSR1GAAMEN1KMT2A | |
| SCHEMBL13451785 | 0.77 | TDP1 (0.57) | TDP1NPSR1GAAMEN1KMT2A | |
| SCHEMBL23695346 | 0.76 | NPSR1 (0.37) | TDP1NPSR1GAAMEN1KMT2A | |
| SCHEMBL29549866 | 0.76 | TDP1 (0.59) | TDP1NPSR1GAAMEN1KMT2A | |
| SCHEMBL18689368 | 0.76 | NPSR1 (0.37) | TDP1NPSR1GAAMEN1KMT2A | |
| SCHEMBL14680159 | 0.76 | TDP1 (0.59) | TDP1NPSR1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914233-B1 | Silyl-protected hydroxymethyl-carbamoylalkyl-ketones as intermediates in the preparation of dopamine-beta-hydroxylase inhibitors | PORTELA & CA SA (PT) | 2011-03-02 | — | — | EP | claimed |
| EP-3808737-A1 | PROCESSES FOR PREPARING MEDICAMENTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND INTERMEDIATES FOR USE THEREIN | BIAL - Portela & Ca., S.A. (PT) | 2021-04-21 | — | — | EP | disclosed |
| EP-3044215-B1 | PROCESSES FOR PREPARING MEDICAMENTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND INTERMEDIATES FOR USE THEREIN | BIAL PORTELA & CA SA (PT) | 2020-04-29 | — | — | EP | disclosed |
| US-10329268-B2 | Processes for preparing medicaments for the treatment of cardiovascular diseases and intermediates for use therein | BIAL-PORTELA & CA, S.A. (PT) | 2019-06-25 | — | — | US | disclosed |
| US-20160221981-A1 | Processes for Preparing Medicaments for the Treatment of Cardiovascular Diseases and Intermediates for Use Therein | BIAL-PORTELA & CA., S.A. (PT) | 2016-08-04 | — | — | US | disclosed |
| EP-3044215-A1 | PROCESSES FOR PREPARING MEDICAMENTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND INTERMEDIATES FOR USE THEREIN | Bial-Portela & CA, S.A. (PT) | 2016-07-20 | — | — | EP | disclosed |
| WO-2015038022-A1 | PROCESSES FOR PREPARING MEDICAMENTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND INTERMEDIATES FOR USE THEREIN | BIAL - PORTELA & CA., S.A. (PT) | 2015-03-19 | — | — | WO | disclosed |
| US-8957222-B2 | Process for preparing intermediates of peripherally-selective inhibitors of dopamine-β-hydroxylase involving catalytic asymmetric hydrogenation | BIAL-PORTELA & CA, S.A. (PT) | 2015-02-17 | — | — | US | disclosed |
| EP-2303855-B1 | CATALYTIC PROCESS FOR ASYMMETRIC HYDROGENATION | BIAL PORTELA & CA SA (PT) | 2014-12-31 | — | — | EP | disclosed |
| US-8710239-B2 | Process for preparing synthetic intermediates of peripherally-selective inhibitors of dopamine-β-hydroxylase involving catalytic asymmetric hydrogenation | BIAL—Portela & C.A., S.A. (PT) | 2014-04-29 | — | — | US | disclosed |
| EP-1914233-A1 | Peripherally-selective inhibitors of dopamine-b-hydroxylase and method of their preparation | Portela & Ca., S.A. (PT) | 2008-04-23 | — | — | EP | disclosed |
| EP-1911757-A2 | Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors | Portela & Ca., S.A. (PT) | 2008-04-16 | — | — | EP | disclosed |
| EP-1908759-A2 | 3,4-dihydro-3-amino-2H-1-benzopyrane and -benzothiopyrane derivatives as dopamine-beta-hydroxylase Inhibitors and methods of their preparation | Portela & Ca., S.A. (PT) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908760-A1 | Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation | Portela & Ca., S.A. (PT) | 2008-04-09 | — | — | EP | disclosed |
| US-7259271-B2 | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2007-08-21 | — | — | US | disclosed |
| US-20070015730-A1 | Peripherally-Selective Inhibitors of Dopamine-ß-Hydroxylase And Method Of Their Preparation | PORTELA & C.A., S.A. (PT) | 2007-01-18 | — | — | US | disclosed |
| US-7125904-B2 | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2006-10-24 | — | — | US | disclosed |
| US-20040142996-A1 | Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2004-07-22 | — | — | US | disclosed |
| WO-2004033447-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS PERIPHERALLY-SELECTIVE INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE | PORTELA & C.A., S.A. (PT) | 2004-04-22 | — | — | WO | disclosed |
| EP-1408038-A2 | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | Portela & Ca., S.A. (PT) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142996-A1 | Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation | DBH, ADRB1, ADRB3 | TDP1 914/4885NPSR1 257/4885GAA 2321/4885 |
| US-20070015730-A1 | Peripherally-Selective Inhibitors of Dopamine-ß-Hydroxylase And Method Of Their Preparation | DBH, PAH, TH | TDP1 586/4885NPSR1 230/4885GAA 1946/4885 |
| US-10329268-B2 | Processes for preparing medicaments for the treatment of cardiovascular diseases and intermediates for use therein | DBH, COMT, ADRB3 | TDP1 2031/4885NPSR1 225/4885GAA 661/4885 |
| US-20160221981-A1 | Processes for Preparing Medicaments for the Treatment of Cardiovascular Diseases and Intermediates for Use Therein | DBH, COMT, ADRB3 | TDP1 2031/4885NPSR1 225/4885GAA 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.